Stratagen Quantitative Prostate MRI Platform Pilot Study
Interventionnel
Phase non listée
Urology Clinic at Sawgrass
The goal of this clinical trial is to assess the safety and feasibility of the Stratagen Quantitative Prostate MRI Platform when used in addition to the standard scans conducted during the existing prostate MRI sessions.
* What severe problems, if any, occur because of the use of the Stratagen Quantitative Prostate MRI Platform? * Can the data collected be used to measure quantitative MRI parameters?
Participants will:
- Receive up to 15 minutes of additional MRI scan time during the existing prostate MRI imaging session.
Catégorie de traitement
Dispositif
Mutations requises
Aucun
Essai commencé
2025-09-24
Dernière mise à jour par le sponsor
2025-10-21
Achèvement estimé
2025-11-30
Éligibilité
Critères d'inclusion
* Subject has a prostate that would be considered for biopsy
* Age 40-90 years
* PSA ≥ 2.5
* Subject has been informed of the nature of the study and has provided written informed consent
Critères d'exclusion
* Contraindication for MRI
* Prostate biopsy within the previous 12 weeks
* Implant in the pelvis that may cause artifact on MRI (e.g. hip replacement)
* History of prostatectomy or other local prostate cancer therapy (e.g., cryotherapy or brachytherapy), or previous pelvic irradiation
* Currently enrolled in another investigational drug or device study that clinically interferes with this study
* Unable to comply with the study requirements or follow up schedule
* Any condition the Investigator believes would interfere with the intent of this study or would make participation not in the best interest of the subject
Pensez-vous que cet essai apparaît incorrectement ?
Détails de la conception
AllocationN/A
Modèle d'interventionSingle Group Assignment
MasquageNone (Open Label)
Nombre à inscrire45
Bras et interventions
Bras
Interventions
Type : Experimental
Description :
Interventions :
MRI
Mesures des résultats
Mesures des résultats primaires
Safety: no SAEs attributable to the Stratagen Quantitative Prostate MRI Platform, as determined by participating Investigator according to CTCAE guidelinesBeginning of MRI Scan to end of MRI scan (MRI Scan Visit, Day 0)
All serious adverse events attributable to the Stratagen Quantitative Prostate MRI Platform will be reported.
• Feasibility: collection of the data necessary to produce measurable quantitative T1 and T2 relaxation times (milliseconds) maps (images) for at least 80% of pixels fully contained within the prostate for at least 80% of subjectsBeginning of MRI Scan to end of MRI scan (MRI Scan Visit, Day 0)
Mesures des résultats secondaires
Aucun
Intéressé à participer ?
En savoir plus sur cet essai et si vous pourriez être éligible à participer.
Mettre l'essai en favori
Partager l'essai par e-mail
Télécharger l'essai
Pensez-vous que cet essai apparaît incorrectement ?
Signaler l'essai
Télécharger l'essai
Sites d'essai
Cette étude compte 1 site d'essai
Urology Clinic at Sawgrass Rochester, New York, US